CDK9 and cancer: Wang and coworkers utilized a strategy focused on substitution of both the A- and B-rings of wogonin at C8 and C4′, respectively, in search of optimized cyclin-dependent kinase 9 (CDK9) inhibitors for the treatment of cancer [83].